Environmental manganese (Mn) toxicity causes an extrapyramidal, parkinsonian-type movement disorder with characteristic magnetic resonance images of Mn accumulation in the basal ganglia. We have recently reported a suspected autosomal recessively inherited syndrome of hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia in cases without environmental Mn exposure. Whole-genome mapping of two consanguineous families identified SLC30A10 as the affected gene in this inherited type of hypermanganesemia. This gene was subsequently sequenced in eight families, and homozygous sequence changes were identified in all affected individuals. The function of the wild-type protein and the effect of sequence changes were studied in the manganese-sensitive yeast strain Dpmr1. Expressing human wild-type SLC30A10 in the Dpmr1 yeast strain rescued growth in high Mn conditions, confirming its role in Mn transport. The presence of missense (c.266T>C [p.Leu89Pro]) and nonsense (c.585del [p.Thr196Profs*17]) mutations in SLC30A10 failed to restore Mn resistance. Previously, SLC30A10 had been presumed to be a zinc transporter. However, this work has confirmed that SLC30A10 functions as a Mn transporter in humans that, when defective, causes Mn accumulation in liver and brain. This is an important step toward understanding Mn transport and its role in neurodegenerative processes.
Introduction
Manganese (Mn) is an essential trace metal that plays a critical role as a cofactor for a variety of enzymes involved in amino acid, lipid and carbohydrate metabolism, immune function, bone and connective tissue growth, and blood clotting. 1 The main source of Mn in humans is through dietary ingestion. Stable tissue levels are maintained by tight homeostatic control of intestinal absorption and biliary excretion of Mn. 2 Although Mn is critical for cell function, overexposure is known to be neurotoxic and causes ''manganism.'' This distinct syndrome of extrapyramidal movement disorder combined with high signal intensity of the basal ganglia on T1-weighted magnetic resonance images (MRI) of the brain is caused by Mn accumulation in the basal ganglia. 3, 4 Most frequently, hypermanganesemia occurs because of environmental overexposure. It has been described in workers in mining and welding industries who inhale Mn-laden dust or fumes 3, 5, 6 and in individuals ingesting contaminated drinking water. 7 However, cases of Mn intoxication have also been observed in drug addicts who use intravenous methcathinone contaminated with potassium permanganate 8, 9 and in children and adults receiving parenteral nutrition. 10, 11 Acquired hepatocerebral degeneration (AHD) can develop in individuals with impaired biliary excretion of Mn including those with advanced hepatic cirrhosis or portosystemic shunts causing a debilitating motor disorder. [12] [13] [14] [15] Predisposition to Mn toxicity has also been suggested in individuals with idiopathic Parkinson's disease (PD). 16, 17 Indeed, it has been reported that the use of methylcyclopentadienyl manganese tricarbonyl (an organic derivative of Mn) as an octane enhancer in gasoline might result in earlier presentation of PD. 18 Although manganism resembles PD (with symptoms of generalized bradykinesia and rigidity), there are characteristic features distinguishing Mn intoxication from idiopathic PD. Manganism more frequently causes dystonia, shows poor therapeutic response to levodopa, and has normal fluorodopa uptake by PET scan. 19, 20 Several cases of hypermanganesemia, dystonia, and polycythemia with a variable degree of hepatic dysfunction have been described in children without significant environmental Mn exposure. [21] [22] [23] [24] [25] [26] Identification of two affected siblings, from a consanguineous family, with this disorder suggested an inherited defect of Mn homeostasis [MIM 613280 ]. 21 We have identified a further 13 individ-them previously reported, [22] [23] [24] and performed homozygosity mapping to identify the affected gene. 
Material and Methods

Subjects
For clinical details see Results and Table 1 . The research protocol was approved by the West London Research Ethics Committee. All participants provided written informed consent for participation in the study.
Homozygosity Mapping
Affected and unaffected siblings of two consanguineous families were included in homozygosity mapping studies. For pedigrees see Figure S1A , available online. Total genomic DNA was extracted from whole blood of affected individuals with the Gentra Puregene Blood Kit (QIAGEN). Whole-genome mapping was performed with the Illumina HumanCytoSNP-12 DNA Analysis BeadChipKit according to the manufacturer's instructions. SNP data were analyzed with Illumina GenomeStudio Software to identify areas of homozygosity in affected individuals. Corresponding gene lists were generated for each area of homozygosity with the National Center for Biotechnology Information (NCBI) genome viewer build 36.3.
Sequencing of SLC30A10
The four exons and exon-intron boundaries of the coding sequence of SLC30A10 (NM_018713.2) were amplified by PCR from genomic DNA (primers listed in Table S1 ). The amplicons were purified with shrimp alkaline phosphatase and exonuclease I and subsequently sequenced bidirectionally with the ABI BigDye Terminator 1.1 system (Applied Biosystems) on an ABI DNA sequencer. Sequence data were analyzed with the Sequencer 4.9 software (Gene Codes). Mutations were confirmed by restriction enzyme digest test (enzymes obtained from New England Biolabs). Two hundred control alleles of healthy individuals (who were, where possible ethnicity matched) were screened by restriction enzyme digest test or sequencing for each mutation to exclude common variants.
Sequence Alignment and Phylogeny
Members of the SLC30A10 and Zrc1 family were identified with Ensembl and NCBI. Sequences were aligned with ClustalW2 and the neighbor-joined dendrogram generated with ClustalX. 27 For protein accession numbers see Table S2 .
Yeast Expression Studies
Expression studies were performed with Gateway technology (Invitrogen). AttB site-introducing primers were designed according to the manufacturer's instructions (Table S3) . cDNA was synthesized from human fetal liver total RNA (purchased from Stratagene) with the SuperScript III First-Strand Synthesis System (Invitrogen), and SLC30A10 was amplified with Platinum Pfx DNA Polymerase (Invitrogen). Similarly, ZRC1 was amplified from Saccharomyces cerevisiae genomic DNA (purchased from Novagen). The PCR products were purified with 30% PEG 8000/ 30mM MgCl 2 . Entry clones of SLC30A10 and ZRC1 were produced with the pDONR221 vector and BP Clonase II enzyme mix (Invitrogen). OneShot OmniMAX 2-T1 chemically competent Escherichia coli cells were transformed with the BP recombination reaction and entry clones selected on LB agar plates containing Kanamycin (50 mg/ml). After plasmid extraction with the QIAGEN Plasmid Mini Kit and DNA sequencing of the plasmid insert, a clone with the correct insert sequence of SLC30A10 or ZRC1 was selected and used for site-directed mutagenesis.
Site-directed mutagenesis, with SLC30A10/pDONR221 and ZRC1/pDONR221 as DNA templates, was performed with the QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene) according to manufacturer's instructions (primers are listed in Table  S4 ). OneShot OmniMAX 2-T1 chemically competent E. coli cells were transformed with the mutated vectors as described above and mutations confirmed by DNA sequencing after plasmid extraction.
Expression 
Results
Clinical Characteristics of Affected Individuals
Affected individuals present at the age of 2 to 15 years with gait disturbance and hypertonia of the limbs with some becoming wheelchair bound. Although most cases show pure four-limb dystonia leading to a characteristic highstepping gait (a ''cock-walk'' gait) and fine motor impairment sometimes accompanied by dysarthria, fine tremor, and bradykinesia, one affected individual has pure spastic paraparesis without extrapyramidal dysfunction (Table 1) . 22 Childhood developmental milestones are ageappropriate, and intellectual development appears normal in affected individuals; however, no formal cognitive testing was performed. All cases have pathognomonic MRI brain appearances with hyperintensity of globus pallidus, putamen, caudate, subthalamic and dentate nucleus and sparing of the thalamus and ventral pons on 
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T1-weighted images ( Figure S2 ). When the disease is extensive, this can be accompanied by white matter and anterior pituitary involvement. T2-weighted images also show changes, however, to a much lesser extent, and are often reported as normal. Most affected individuals have liver impairment suggested by raised transaminases and unconjugated hyperbilirubinemia, and two individuals have died following complications of cirrhosis (Table 1) . Liver biopsies show micronodular cirrhosis or fibrosis with positive rhodanine staining and elevated Mn content. 21, 22 Whole-blood Mn levels are significantly raised in all affected individuals (on average more than 2,000 nmol/l; normal is less than 320 nmol/l) ( Table 1) , mostly to a much higher extent than observed previously in environmental Mn exposure, 3,7 parenteral nutrition, 10 or chronic liver disease 21 where blood levels are less than 2,000 nmol/l. Parental blood Mn levels were mildly elevated in three families (380 to 649 nmol/l), consistent with carrier status. These parents and heterozygous siblings were asymptomatic and were therefore not subjected to detailed evaluation of neurological and hepatic function.
Further features generally observed in this form of inherited hypermanganesemia are polycythemia associated with high erythropoietin levels and depleted iron stores indicated by low ferritin and iron levels and increased total iron binding capacity (Table 1) .
Chelation therapy with disodium calcium edetate as recommended for environmental Mn intoxication 28 has been initiated in some individuals with improvement of neurological symptoms. Supplementation of iron, a competitive inhibitor of intestinal Mn uptake 29, 30 in individuals with low iron stores, has also proven effective to lower blood Mn levels. A significant reduction in blood Mn levels, normalization of the erythrocyte count, and improvement of neurological symptoms was observed in individual D-II-6 21 and G-II-2 ( Figure S3 ). Long-term follow-up data of manganese blood levels is currently only available for individual D-II-6. Combined disodium calcium edetate and iron supplementation has resulted in significant improvement of gait and fine motor movements, resolution of polycythemia, and normalization of liver Mn content with no further progression of cirrhosis. Table S5 ).
This area contained only one gene, SLC30A10, and this was considered a strong candidate gene. Analysis of coordinate data suggested that exons 1 and 2 of this gene were affected by the deletion in family A.
Sanger Sequencing of SLC30A10 Sequencing of SLC30A10 in individual D-II-6 revealed a homozygous nine base deletion in exon 1 (c.314_322del) resulting in a deletion of three amino acids (p.Ala105_ Pro107del) ( Figure S4 ). Both parents and three unaffected siblings of family D were heterozygous for the mutation. All other healthy siblings did not carry this mutation. The sequencing data were confirmed by a restriction enzyme digest test that used MspI (data not shown). This mutation was absent in 200 control alleles of healthy individuals.
Subsequent mutation analysis of SLC30A10 in a further six families revealed homozygous sequence changes in all affected individuals (Figure 1 ). Where DNA of parents was available, they were found to be heterozygous carriers. None of the unaffected siblings were homozygous for the familial mutation and mutations were absent in 200 control chromosomes of healthy unaffected individuals. Amplification of SLC30A10 from blood, lymphoblastoid, and fibroblast cDNA from healthy control subjects was unsuccessful suggesting that SLC30A10 is not expressed in these cell lines. This is consistent with previous studies in rats showing tissue specific expression in liver, brain, and intestine. 31 Unfortunately, such tissue samples in a form suitable for RNA analysis were not available from affected individuals.
Sequence Alignment and Phylogeny SLC30A10 sequence alignment of various species with its ortholog in fungi, Zrc1, confirmed that all identified amino acid substitutions affect evolutionary highly conserved areas of the protein (Figure 2 ). The phylogeny tree shows the two distinct evolutionary groups of SLC30A10 and Zrc1 ( Figure S5 ).
Yeast Expression Studies
The function of human wild-type SLC30A10 and the effect of mutations were investigated in the Mn-sensitive Dpmr1 yeast strain. 
32-34
Out of the eight identified mutations, we chose to investigate two different types of sequence changes: one missense mutation (c.266T>C), which is located in a highly conserved transmembrane region, and one nonsense mutation (c.585del) predicted to lead to the production of a significantly truncated protein of 213 amino acids (p.Thr196Profs*17; Figure 2 ). Both mutations were created with site-directed mutagenesis. ZRC1, the yeast ortholog of SLC30A10, and ZRC1 with its previously described Mn resistant mutation (c.131A>T) were used as controls. 32 The Dpmr1 yeast strain failed to grow on SC-Ura medium supplemented with a high Mn concentration (1.5 mM MnCl 2 ) (Figure 3) . Overexpression of the wild-type human SLC30A10 inserted into the yeast expression vector pYES-DEST52 under the control of the GAL1 promoter restored growth under high Mn concentrations suggesting its crucial role in Mn transport. The presence of the missense (c.266T>C) and nonsense (c.585del) mutation in SLC30A10 abolished growth (Figure 3 ).
Discussion
We have identified the genetic basis of an inborn error of Mn homeostasis with accumulation of Mn in the liver and basal ganglia; it is caused by mutations in SLC30A10.
Human SLC30A10 is on chromosome 1 and has four exons that encode a protein of 485 amino acids (NP_061183.2) (Figure 1 ). This gene was recently identified by bioinformatics methods and was classified as a member of the SLC30 solute carrier subfamily of the cation diffusion facilitator (CDF) family. 35 To date the SLC30 family has been thought to be a group of mammalian Zn transporters. 35, 36 Proteins of this family have a conserved structure of six transmembrane helices (TMD I-VI) with both N and C termini located on the cytoplasmic side of the plasma membrane. 35, 37 Solute carriers are secondary active transporters allowing movement of molecules across a cell membrane against a concentration gradient without the direct use of ATP. Members of this family are found in all biological kingdoms and transfer metals out of the cytosol, either extracellularly or into organelles, thereby regulating intracellular metal concentrations. 31, [35] [36] [37] [38] Mutation analysis of SLC30A10 revealed homozygous sequence changes in all affected individuals described. These are predicted to either cause a significantly truncated protein because of a frameshift and premature stop codon or are deletions or affect an evolutionary highly conserved area of the protein and are therefore likely to have a detrimental effect on protein function (Figure 2 ). All identified sequence changes were absent in 200 control chromosomes of healthy individuals and are not listed as SNPs on dbSNP and Ensembl databases. Analysis of variants in the general population reported on dbSNP and Ensembl identified two SNPs in the coding region of SLC30A10 that are predicted by the bioinformatic tools PolyPhen and SIFT to be damaging to protein function (Table S6) . However, both are rare in the general population, 1:4,551 and 1:4,548, respectively. It will be of interest to study these variants and establish whether they are pathological mutations.
The deleterious effects of mutations in this gene were confirmed by expression studies in the Mn-sensitive Dpmr1 yeast strain. Although wild-type SLC30A10 restored growth in high Mn concentrations, SLC30A10 carrying a missense (c.266T>C) or nonsense (c.585del) mutation did not (Figure 3) . Not very surprisingly, the effect of human wild-type SLC30A10 in yeast was less pronounced than that of ZRC1 carrying the Mn resistance mutation (c.131A>T). SLC30A10 and Zrc1 (p.Asn44Ile) probably both contribute to Mn uptake into vacuolar vesicles; how this actually occurs and whether there are different mechanisms involved has yet to be determined.
Our studies demonstrate that human wild-type SLC30A10 functions as a Mn transporter that protects cells from Mn toxicity. Amino acid substitutions in the SLC30A10 yeast ortholog Zrc1 have recently been reported to alter substrate specificity from Zn to iron and Mn. 33 Evolutionary changes in the amino acid sequence might be responsible for the altered metal affinity in man.
CDF transporters share a high degree of sequence conservation in the charged residues of TMD II and V that are thought to function as specific metal binding sites. Zn binding in YiiP, an E. coli CDF member, is facilitated by two highly conserved aspartic acid residues (position 45 and 49) in TMD II and a histidine and aspartic acid (position 153 and 157) in TMD V. 39, 40 Several residues within TMD II, III, and IV of Zrc1 are also known to be critical for zinc specificity 33, 41 Alignment of the protein sequences of Zrc1 and SLC30A10 from different species revealed that during evolution Leu33, Asn44, and Ala52 in TMD II and Ser272 and Ile275 in TMD IV have been replaced by Ile, Ser, Gly, The, and Met in SLC30A10, respectively (Table 2) . 41 These amino acids appear to be highly conserved throughout the SLC30A10 family. Lack of conservation of these amino acids between Zrc1 and SLC30A10 suggests that they have evolved independently and functionally as two different transporters. The Zrc1 subfamily contains mostly prokaryotic members from both eubacterial and archaeal sources, whereas the SLC30A10 subfamily contains eukaryotic members ( Figure S5 ). Therefore, we conclude that evolutionary changes in the amino acid sequence of the protein have altered the substrate specificity of the transporter from Zn in yeast to Mn in mammalian cells. This is consistent with the finding that affected individuals carrying a mutation in SLC30A10 have high blood Mn levels, whereas Zn levels are normal. Although we have not excluded the possibility that SLC30A10 might be involved in the transport of other divalent cations, the mutations that we have encountered in this gene only result in a hypermanganesemia phenotype and other blood cation levels are within the normal range. Further studies are required to investigate the properties of SLC30A10 and determine how SLC30A10 is involved in the regulation of Mn transport. Mn homeostasis in higher organisms is not well understood. Various cellular uptake mechanisms for Mn have been suggested, including divalent metal transporter (DMT1), ZIP-8, the transferrin (Tf)/Tf receptor (TfR) system, voltage and store operated calcium channels, and the glutamate receptor channel; however, none of these transporters are specific for Mn. 1, 42, 43 Given that mutations in SLC30A10 in humans have a detrimental effect on Mn homeostasis, we expect that SLC30A10 is a key player in Mn transport. Neurological presentation of individuals with a syndrome of hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia resembles environmental Mn toxicity and AHD, both presenting with atypical parkinsonism that is poorly responsive to L-Dopa treatment. 3, 6, 14, 15 Although dystonia and rigidity are more prominent in inherited hypermanganesemia and environmental manganism, AHD is more likely to cause ataxia and chorea. 14 Figure S2 ). 4, 14, 15 The most characteristic finding in inherited hypermanganesemia is increased signal intensity of the globus pallidus on T1-weighted sequences with changes extending into adjacent basal ganglia in most cases. When the disease is extensive, white matter involvement can be observed. More frequently than seen in occupational manganism and AHD, T2 changes of low signal return from the globus pallidus are also present in inherited hypermanganesemia. However, there are no specific MRI features that can distinguish SLC30A10 mutations from acquired causes of hypermanganesemia. One affected individual has a different neurological phenotype of spastic paraparesis without extrapyramidal motor impairment. 22 This presentation is similar to hepatic myelopathy, a rare complication of hepatic failure that has also been attributed to Mn accumulation. 44 In both cases, MRI of the spinal cord is normal. Although cirrhosis has not been observed in environmental Mn exposure, it is the life-limiting factor in this form of inherited hypermanganesemia. The liver is the major organ involved in the excretion of Mn via the bile. In animal models increased exposure to Mn results in hepatocellular necrosis and elevated transaminases. 45, 46 Polycythemia and depleted iron stores are hallmarks of this disease and should prompt SLC30A10 analysis. Both features have not been observed in cases of environmental Mn toxicity and AHD. Individuals with a diagnosis of cryptogenic liver cirrhosis and AHD should be carefully assessed for these features to allow correct diagnosis. Mn has been suggested to induce erythropoietin gene expression, 47 and this is the likely mechanism behind the development of polycythemia in affected individuals. Homeostatic regulation of Mn and iron is closely linked and explains the depleted iron stores in affected individuals. 1, 29, 42, 48 Mn has a direct effect on the availability of the bioactive iron pool and induces an iron-starved phenotype with reduced ferritin expression and increased TfR expression. With increasing exposure to Mn, release of iron from intracellular stores, enhanced iron uptake, and decreased iron utilization is favored. 49, 50 Iron and Mn are chemically and structurally similar and compete for the same serum binding protein (Tf) and membranous transporter protein (DMT1). Therefore, dietary iron status has a direct effect on Mn uptake. 29, 30 This explains the beneficial effect of iron supplementation in affected individuals. Chelation therapy to enhance urinary Mn excretion has been attempted with various chelation agents. Disodium calcium edetate as recommended for environmental Mn intoxication 28 has significantly improved neurological symptoms in some subjects, led to reduction of blood Mn, and halted the progression of cirrhosis. 21 It carries the disadvantage of intravenous application over 5 days every 4 weeks and the requirement of strict monitoring of other essential heavy metals such as zinc, copper, and selenium. 51 Several of the affected individuals are from countries with poor medical resources where intravenous disodium calcium edetate is either not available or the current setting would not allow for frequent application and monitoring of chelation therapy. Other chelating agents have therefore been used. Two siblings (B-II-2 and B-II-5) have improved clinically on oral dimercaptosuccinic acid (DMSA). However, because both siblings also receive iron supplementation, it is difficult to attribute the effect to one or the other. Blood and urine Mn levels and neurological symptoms of two men with occupational Mn intoxication did not respond significantly to DMSA treatment. 52 Para-aminosalicylic acid has also been reported not to be beneficial. 23 Further research is required to identify specific and efficacious treatment agents for hypermanganesemia that can be administered conveniently, preferably by mouth. Chronic exposure to Mn has been suggested to be involved in the pathogenesis of PD. [53] [54] [55] [56] [57] Whole-blood Mn levels in a PD cohort have been found to be significantly higher than in healthy control subjects. 55 56, 57 Therefore, the importance of understanding Mn homeostasis in more detail is becoming increasingly evident. In summary, by studying a rare syndrome of inherited Mn accumulation, we have identified a unique Mn transporter in man. SLC30A10 has been shown to function as a specific Mn transporter in higher organisms and when mutated causes a syndrome of hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia characterized by accumulation of Mn in liver and brain.
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